Skip to content

Ketamine for depression: all studies

Page 171 of 173: studies 1,701 to 1,710 of 1,728, newest first. Back to the ketamine for depression overview

Research

Magnesium level and impulsivity during ketamine administration for treatment-resistant mood disorders.

Magnesium Research Jakub Słupski, Adam Włodarczyk, Natalia Górska et al.

Impulsive behaviours affect patients with major depressive disorder (MDD) and bipolar disorder (BP), increasing suicide risk and mood instability. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has been reported to promote fast-acting antidepressive and antisuicidal effects. Magnesium administered contemporarily with low-dose NMDA antagonists has been shown to cause a reduction...

DOI: 10.1684/mrh.2024.0534 (opens in new tab) Full text (opens in new tab) Impulsivity Mood disorders Ketamine therapy Treatment-resistant depression trd +2

Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends.

American Journal of Therapeutics Amna M. Aslam, Kenneth Shinozuka, Owen S. Muir et al. 5 citations

Ketamine has emerged as a novel treatment for psychiatric disorders, particularly treatment-resistant depression (TRD). Although intravenous (IV) ketamine is not approved by the Food and Drug Administration (FDA) for TRD, esketamine, an FDA-approved therapeutic, has contributed to the widespread clinical use of off-label IV ketamine across the United States. This scoping review highlights...

Intranasal esketamine in treatment resistant depression – a double-blind, randomized, efficacy and dose response study

Ella Daly, Jaskaran Singh, Maggie Fedgchin et al.

Background: Intravenous ketamine and esketamine (ESK) produce rapid antidepressant action in treatment-resistant depression (TRD) patients, however dose response is not known. Study assessed efficacy, dose response and safety of intranasal ESK and ability to sustain response with gradual tapering of treatment frequency. Methods: In the Panel A (conducted in USA and Belgium) of this...

Neural Correlates of the DEEPP (Anti-suicidal Response to Ketamine in Treatment-Resistant Bipolar Depression) Study: Protocol for a Pilot, Open-Label Clinical Trial (Preprint)

Yuliya Knyahnytska, Reza Zomorrodi, Tyler S Kaster et al.

BACKGROUND Suicide is among the top 10 leading causes of death worldwide. Of people who died by suicide, the majority are diagnosed with depression. It is estimated that 25%-60% of people with bipolar depression (BD) will attempt suicide at least once, and 10%-15% will die by suicide. Several treatments, such as lithium, clozapine, electroconvulsive therapy, and cognitive behavioral therapy,...

Single I.V.-ketamine Augmentation of Newly Initiated Venlafaxine Hydrocortisone for Treatment-resistant Depression: Randomized, Double-blind Controlled Study Protocol

Yun Du, Ruobing Feng, Wenle Zhang et al. preprint

Abstract Background: The critical issue of treating Treatment-Resistant Depression (TRD) is to improve antidepressant effect rapid onset and the recovery rates. Significant antidepressant effects of ketamine onset rapidly, but decay rapidly and repeated dosing increases the risks. This study aimed to explore the efficacy and safety of single intravenous ketamine, combined with venlafaxines...

Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: A retrospective chart review

Danika Dai, Courtney Miller, Violeta Valdivia et al. preprint

Abstract BackgroundKetamine has emerged as a rapid-acting antidepressant in treatment-resistant depression (TRD) increasingly used in non-research, clinical settings. Few studies, however, have examined neurocognitive effects of repeated racemic ketamine infusion treatments in patients with TRD. In an effort to identify potential effects after serial infusions, we conducted a retrospective...

Subcutaneous and Intramuscular Parental Ketamine for Treatment of Depression: Clinical Treatment Protocol

Joseph C.W. Tham, André Do, Jason Fridfinnson et al. preprint

Intravenous (IV) ketamine has been shown to have rapid antidepressant effects in individuals with treatment-resistant depression (TRD). This treatment protocol describes a clinical method for use of subcutaneous (SC) and intramuscular (IM) racemic ketamine in individuals with TRD, developed by a team at the University of British Columbia (UBC), UBC Hospital, and Vancouver General Hospital. The...

Intravenous ketamine is ineffective compared to midazolam for treatment-resistant depression: a double-blind, randomized controlled study

Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. preprint

Abstract Background: Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent...

Randomized Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for Treatment-Resistant Depression – the BEDROC Study

Paul Glue, Colleen Loo, Johnson Fam et al. preprint

Abstract Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended release tablet (R-107), compared with other routes of administration. In this phase 2 multicentre clinical trial, adult patients with TRD and Montgomery-Asberg Depression Rating...

Esketamine relieves postoperative depression and pain indicators in patients undergoing laparoscopic total hysterectomy

Jun Jing, Meng-Ying Zhang, Wei-hong Yin et al. preprint

Abstract Objective To observe the effects of esketamine on postoperative depression and pain indicators in individuals undergoing total laparoscopic hysterectomy. Methods 135 patients undegoing total laparoscopic hysterectomy were recruited and randomly allocated to three groups. Finally, a total of 127 patients were selected into the statistical analysis, with the final grouping information as...